Last updated: March 13, 2026
What is NDC 60219-1705?
NDC 60219-1705 refers to Vabysmo (faricimab-svoa), a vascular endothelial growth factor (VEGF) and Angiopoietin-2 inhibitor authorized for the treatment of age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It was approved by the FDA in January 2022.
Market Landscape
Target Indications
- Age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
Market Size (2023)
| Indicator |
Value (USD billions) |
Source |
| Global retinal disorder market |
8.5 |
Market Research Future (2022) |
| AMD segment |
4.2 |
Grand View Research (2022) |
| DME segment |
2.3 |
MarketsandMarkets (2022) |
| RVO segment |
1.1 |
Mordor Intelligence (2022) |
Competitive Landscape
| Product |
Mechanism |
Market Share (2023) |
Pricing (per injection) |
Notes |
| Lucentis (ranibizumab) |
Anti-VEGF |
45% |
$2,000 – $2,400 |
Market leader historically |
| Eylea (aflibercept) |
Anti-VEGF |
40% |
$1,900 – $2,200 |
Competitive with Lucentis |
| Beovu (brolucizumab) |
Anti-VEGF |
10% |
$1,900 |
Market entry in late 2019 |
| Vabysmo (faricimab) |
Dual VEGF and Ang-2 inhibition |
4% (2023 estimate) |
$2,020 |
Recently launched; projected growth |
Adoption and Market Penetration
Vabysmo is in early adoption phase, with rapid expansion expected due to differentiated mechanism targeting both VEGF and Ang-2 pathways. Insurers are beginning to include it in formularies, influencing payer dynamics.
Price Projections (2023-2030)
Initial Pricing (2023)
- Price per intravitreal injection is approximately $2,020
- Number of injections per year: 4-6, depending on the indication and patient response
Revenue Projections
| Year |
Estimated Units Sold (millions) |
Total Revenue (USD billions) |
Assumptions |
| 2023 |
1.3 |
2.6 |
Early adoption, limited coverage |
| 2024 |
2.0 |
4.04 |
Expanded formulary access, increased provider adoption |
| 2025 |
3.2 |
6.46 |
Greater market penetration, more indications approved |
| 2026 |
4.8 |
9.66 |
Increasing use, potential for price negotiations |
| 2027 |
6.5 |
13.13 |
Broader access, insurance coverage stabilizes |
| 2028 |
8.2 |
16.56 |
Mature market, stable pricing |
| 2029 |
9.5 |
19.19 |
Continued growth, potential price adjustments |
| 2030 |
10.5 |
21.21 |
Market saturation, new competitors may influence prices |
Factors Influencing Price and Volume
- Market penetration rate: Rapid in the first five years due to high unmet needs and limited competition.
- Pricing pressure: Payers may negotiate discounts, reducing pricing over time.
- Indication approvals: Expansion into DME and RVO broadens patient pool.
- Emerging competitors: New entries or biosimilars could pressure prices downward.
Price Trends
- Initial high per-injection cost likely to stabilize or decline by 2028-2030 due to increased competition.
- Market will observe a gradual shift towards value-based pricing tied to clinical outcomes.
Regulatory and Payer Dynamics
- FDA approval (January 2022) enabled market entry.
- Payer coverage is evolving, with early reimbursement challenges but improving over time.
- Price negotiations with Medicare and private payers could influence future pricing strategies.
Conclusion: Market Outlook
Vabysmo's market share expansion depends on its clinical benefits, cost-effectiveness, and payer acceptance. Its dual mechanism provides a competitive edge, but high initial pricing limits near-term volume growth. Long-term, a combination of expanded indications, increased provider familiarity, and potential price adjustments could elevate revenues significantly through 2030.
Key Takeaways
- Current market share stands at approximately 4%, with rapid growth projected.
- Price per injection remains around $2,020, with downward pressure expected in later years.
- Total revenue on projections could reach over USD 21 billion annually by 2030.
- Market expansion hinges on broader indication approvals and payer negotiations.
- Emerging competitors could influence both pricing and market share.
FAQs
1. What factors could accelerate Vabysmo's market penetration?
Expanded indication approvals, improved clinician awareness, and favorable payer coverage.
2. How will price negotiations impact long-term revenue?
Payers may push for discounts, potentially reducing per-injection costs by 2028-2030, affecting total revenue growth.
3. What is the main driver of Vabysmo’s differentiated mechanism?
It targets both VEGF and Ang-2 pathways, potentially offering better efficacy for some patients compared to single-target anti-VEGF drugs.
4. How does Vabysmo's pricing compare with competitors?
Its initial per-injection price is comparable to Lucentis and Eylea but could decline faster due to higher competition and biosimilar entries.
5. What are potential risks to market growth?
Emergence of new therapies, changes in reimbursement policies, and lower-than-expected adoption rates.
References
- Grand View Research. (2022). Age-related macular degeneration market report.
- MarketsandMarkets. (2022). Diabetic retinopathy and DME therapeutics.
- Mordor Intelligence. (2022). Retinal vein occlusion market.
- Market Research Future. (2022). Retinal disorder global market analysis.
